Showing results (461-470 of 576) with videos related to

Sort By:
Pageof 58
Journal of Hematology & Oncology|May 2, 2023
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemiaHagop Kantarjian, Fadi G Haddad, Nitin Jain, et al.
Haematologica|October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitorNicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
American Journal of Hematology|July 29, 2023
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failureSamuel Urrutia, Kelly S Chien, Ziyi Li, et al.
Physiology & Behavior|June 18, 2025
Gut microbiome is associated with insula structure in neonatesMichelle Graf, Nicolas Murgueitio, Margaret A Sheridan, et al.
American Journal of Hematology|January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classificationPatrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.
Blood Advances|April 27, 2023
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantationNicholas J Short, Faustine Ong, Farhad Ravandi, et al.
JAMA Oncology|September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical TrialElias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Blood Cancer Journal|September 30, 2021
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsGhayas C Issa, Jabra Zarka, Koji Sasaki, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
Pageof 58